1. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells
   AGNÈS GARNIER et al, 2015 CrossRef
2. Inhibition of tachykinin NK 1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells
   Samaneh Bayati et al, 2016, European Journal of Pharmacology CrossRef
3. Immunolocalization of Substance P and NK-1 Receptor in ADIPOSE Stem Cells
   Miguel Muñoz et al, 2017, J. Cell. Biochem. CrossRef
4. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells
   Samaneh Bayati et al, 2018, Anti-Cancer Drugs CrossRef
5. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant
   Davood Bashash et al, 2018, The International Journal of Biochemistry & Cell Biology CrossRef
6. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P
   Esra Nizam et al, 2018, Biomedicine & Pharmacotherapy CrossRef
7. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer
   Monireh Davoodian et al, 2019, Mol Biol Rep CrossRef
8. SP/NK‐1R promotes gallbladder cancer cell proliferation and migration
   Xue‐Ting Deng et al, 2019, J Cell Mol Med CrossRef
9. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
   Miguel Munoz et al, 2015, J Biosci CrossRef
10. The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation
    Susana Garcia-Recio et al, 2015, PLoS ONE CrossRef
11. Biological and Pharmacological Aspects of the NK1-Receptor
    Susana Garcia-Recio et al, 2015, BioMed Research International CrossRef
12. The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy
    Agnieszka Majkowska-Pilip et al, 2019, Pharmaceutics CrossRef
13. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.
    Chentao Ge et al, 2019, Proc Natl Acad Sci U S A CrossRef
14. Neurokinin-1 receptor mediated breast cancer cell migration by increased expression of MMP-2 and MMP-14
    Jingyi Li et al, 2016, European Journal of Cell Biology CrossRef
15. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines
    Miguel Muñoz et al, 2017, Pharmacological Reports CrossRef
16. Increased nuclear localization of substance P in human gastric tumor cells
    Miguel Muñoz et al, 2017, Acta Histochemica CrossRef
17. Correlation of Clinicopathological Characteristics of Breast Carcinoma and Depression
    null Ilic et al, 2019, Healthcare CrossRef
18. Neurokinin-1 Receptor Antagonists as Anticancer Drugs
    Miguel Muñoz et al, 2019, LDDD CrossRef
19. The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways
    Hossein Javid et al, 2020, Mol Biol Rep CrossRef
20. The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications
    Charlène Gadais et al, 2020, CMC CrossRef
21. New insight into the role of substance P/neurokinin‐1 receptor system in breast cancer progression and its crosstalk with microRNAs
    Safieh Ebrahimi et al, 2020, Clin Genet CrossRef
22. Targeting tachykinin receptors in neuroblastoma
    Anton G. Henssen et al, 2017, Oncotarget CrossRef
23. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach
    Miguel Muñoz et al, 2020, MRMC CrossRef
24. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
    Miguel Muñoz et al, 2020, JCM CrossRef
25. Detection of neurokinin‐1 receptor by immunohistochemistry in canine mammary gland tumours
    Duri Song et al, 2020, Vet Med Sci CrossRef
26. Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors
    Paweł K. Halik et al, 2020, Molecules CrossRef
27. The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
    Miguel Muñoz et al, 2020, Cancers CrossRef
28. In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity
    Joanna Matalińska et al, 2020, IJMS CrossRef
29. Elevated Neurokinin-1 Receptor Expression in Uterine Products of Conception Is Associated With First Trimester Miscarriages
    Ahmad Alwazzan et al, 2020, Front. Physiol. CrossRef
30. Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity
    Ashiq Legi et al, 2021, Cancers CrossRef
31. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis
    Emma Rodriguez et al, 2021, Cancers CrossRef
32. Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-κB Signal Transduction Pathways in Colon Cancer Cells
    Atefeh Ghahremanloo et al, 2021, BioMed Research International CrossRef
33. Prognostic Significance of Substance P/Neurokinin 1 Receptor and Its Association with Hormonal Receptors in Breast Carcinoma
    Riffat Mehboob et al, 2021, BioMed Research International CrossRef
34. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors
    Julian Kolorz et al, 2021, Current Oncology CrossRef
35. The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification
    Soodabeh Rezaei et al, 2022, BioMed Research International CrossRef
36. The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma
    Mario F. Muñoz et al, 2022, BioMed Research International CrossRef
37. The substance P/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells
    Malihe Golestaneh et al, 2022, Mol Biol Rep CrossRef
38. Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance
    Marilina García-Aranda et al, 2022, Cancers CrossRef
39. Substance P/NK1R Antagonistic Effect of 17-Trifluoromethyl Phenyl Trinor Prostaglandin F2α in Breast Cancer
    Mayuri Mutukuru et al, 2022, Int J Pept Res Ther CrossRef
40. Neuropeptides in Cancer: Friend and Foe?
    Yue Wu et al, 2022, Advanced Biology CrossRef
41. NK1 receptor antagonistic effect of 17-trifluoromethyl phenyl trinor prostaglandin F2α on the growth of human breast cancer cell line
    Mutukuru Mayuri et al, 2022, Experimental and Molecular Pathology CrossRef
42. The Galaninergic System: A Target for Cancer Treatment
    Manuel Lisardo Sánchez et al, 2022, Cancers CrossRef
43. The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells
    Abbas AlAlikhan et al, 2022, Cell Biochem Biophys CrossRef
44. The Neurokinin-1 Receptor: A Promising Antitumor Target
    Rafael Coveñas et al, 2022, Receptors CrossRef
45. High‐Throughput Cellular Heterogeneity Analysis in Cell Migration at the Single‐Cell Level
    Mengli Zhou et al, 2022, Small CrossRef
46. Docking is not enough: 17-trifluoromethylphenyl trinor PGF2α is only a very weak ligand of neurokinin-1 receptor
    Joanna Matalińska et al, 2022, Experimental and Molecular Pathology CrossRef
47. Virtual screening reveals aprepitant to be a potent inhibitor of neutral sphingomyelinase 2: implications in blockade of exosome release in cancer therapy
    Milad Moloudizargari et al, 2023, J Cancer Res Clin Oncol CrossRef
48. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses
    Samine Jafarinezhad et al, 2023, Cell Biochem Biophys CrossRef
49. Harnessing the synergistic potential of NK1R antagonists and selective COX-2 inhibitors for simultaneous targeting of TNBC cells and cancer stem cells
    Madhu Tanya Singh et al, 2024, Journal of Drug Targeting CrossRef
50. Advances in the research and application of neurokinin-1 receptor antagonists
    Xiangyu Hong et al, 2024, J. Zhejiang Univ. Sci. B CrossRef